The concept of myeloproliferative disorders (MPNs) was first described in 1951 by Dr. William Dameshek, the preeminent American clinical hematologist of his time.
Since then, great strides have been made in our understanding of these disorders and in the development of new treatment options. And the research continues to evolve ...
MPN Research Milestones:
1999: The first clinical trial for myeloproliferative disorders, “Combination Chemotherapy Plus Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Myeloproliferative Disorders” is initiated.
2003: The MPD Research Consortium is created to serve as a multi-institution, international group dedicated to establishing clinical trials and conducting basic research into new therapies and treatments.
2005: The JAK2V617F mutation is discovered. JAK2 is the first known genetic mutation associated with myeloproliferative diseases.
2008: Myeloproliferative disorders are reclassified as myeloproliferative neoplasms (MPNs) by the World Health Organization and nested within the blood cancer category.
2011: The first FDA-approved treatment for myelofibrosis, Jakafi, is released.
2013: Calreticulin (CALR) is discovered – a second significant genetic mutation that accounts for the majority of JAK2 negative patients.
18 Nursewood Rd
Tel: 844 644 6766
Our Mission is to stimulate original Canadian research in pursuit of new treatment options - and ultimately a cure - for the blood cancers collectively known as myeloproliferative neoplasms (MPNs).
CRA Registered Charity # 748799723 RR 001